News Across Asia Volume 7 No. 3 (January 2019)

      No Comments on News Across Asia Volume 7 No. 3 (January 2019)

News Across Asia Volume 7 No. 3 (January 2019)

Happy New Year from your family at ISPOR! We wish you and your family a very healthy, prosperous and blessed 2019. We are very pleased to present News Across Asia Pacific January 2019 issue. This issue provides a health policy article on “Capacity-building and Policy Transformation in Health Technology Assessment and Pharmacoeconomics in China,” as well as health systems updates from around the region. We also give you regional news and ISPOR member news. We hope you enjoy this issue and warmly invite you to join ISPOR and learn more about how the Society and ISPOR Asia Consortium are working to improve health care decision making in Asia Pacific and globally.

Kind regards,

News Across Asia Co-Editors Alex Fu, Sang Soo Lee, and Fang Zhang


Health Policy in Asia Pacific

Featured Article

  • The Recent Progress of Capacity-building and Policy Transformation in Health Technology Assessment and Pharmacoeconomics in China

Health Systems Updates

  • Australia – Continuing PBS Reforms
  • Bhutan – Overview of HTA practice
  • India – Policy Perspectives on Real World Evidence
  • Indonesia – Challenges in Conducting HTA and Implementing its Results
  • Hong Kong – Healthcare System Developments
  • Mainland China – New Pricing and Negotiation Structures
  • New Zealand – The Role of Real World Evidence
  • Singapore – Continuing Developments in HTA
  • South Korea – Real World Evidence, HTA and HealthCare Reform
  • Taiwan – Real World Data Experience in HTA and Managed-Entry Agreements for High Cost Drugs

Regional News

  • ISPOR Asia Consortium HEOR Survey – Please Provide Your Feedback
  • Asia Pacific Observatory of WHO SEARO Issued a Call for Reviewers and new Health Systems Publications
  • Survey on Preventing and Controlling NCDs: Welcome your Participation
  • Academic Job Vacancy in Pakistan
  • Textbook Published on Clinical Pharmacy Education, Practice and Research
  • HEOR Certification Program in India
  • Auburn University Health Outcomes Research and Policy PhD Program
  • New 2018-2019 Executive Committee Team for ISPOR Singapore Chapter
  • Upcoming Workshop on “Advanced Modelling Techniques in HTA and RWE Generation” in Singapore
  • ISPOR 2019 Outstanding Regional Chapter Award
  • ISPOR Travel Grant Supports HEOR Professionals from Low- and Middle-Income Countries
  • ISPOR Participation at the National HTA Conference in China
  • 4th WHO Global Forum on Medical Devices in Vishakhapatnam, India
  • Modeling Workshop in the Philippines
  • Training on Pharmacoeconomics held in Mongolia

ISPOR Member News

  • ISPOR Chapter Annual Reports
  • ISPOR Travel Grant Deadlines
  • Conference Abstract Submission Deadlines
  • Chapter Leadership Training Workshop
  • Update your ISPOR Member Profile
  • Asia Consortium Schedule of Events for 2019


Featured Article

The Recent Progress of Capacity-building and Policy Transformation in Health Technology Assessment and Pharmacoeconomics in China

Shanlian Hu, MD, MSc, Professor of Health Economics, School of Public Health, Fudan University, Shanghai, China

At present, China is undergoing an exciting and breakthrough developmental period for health technology assessment (HTA) and pharmacoeconomics. After nearly 20 years of efforts, various conditions for policy development have been met such as speeding up the approval process of new drugs (i.e., anticancer drugs and innovative technologies), and conducting clinical trials simultaneously with the international multicenter studies.

In terms of organizational construction and capacity-building, 8 ISPOR Chapters have been established in mainland China, which cover Hong Kong Chapter, Shanghai Chapter, Chinese Pharmaceutical Association chapter and Chinese Medical Doctor Association Chapter in Beijing, Northeast China Chapter, South China Chapter, West China Chapter and a potentially new chapter called North West Chapter. In the field of HTA, there are also some research centers in the country that conduct the evaluations, such as the National Health Development Research Center in Beijing, and WHO HTA Reference Center at Fudan University in Shanghai, which lay a foundation for organization and competence for future research in China.

Perhaps most encouraging is the restructuring of governmental sectors in 2018. The newly established National Medical Insurance Bureau (NHSA) plays a role as a strategic purchaser which integrates the medical insurance system, bidding and purchasing of drugs, consumables, medical devices, price negotiation and supervision of medical services. For example, the price negotiations of anti-cancer drugs and implementation of waiving the import tax and VAT policy have been done. Recently, 11 pilot municipalities and provincial capital cities in China carried out bulk purchasing with quantity, among them, 22 generic drugs and 3 original drugs were evaluated for quality and consistency with an average price reduction of 52%. The price of drugs was greatly reduced on the premise of guaranteeing the quality and efficacy consistent examination of generics. Furthermore, a pilot project of China-DRG (diagnosis related groups) payment system will be launched nationwide in 2019.

The National Health Commission has also incorporated healthy aging into its function. Recently, it has made breakthroughs in revising the essential medicine list, reforming the price of medical services, implementing health poverty alleviation, promoting the development of the healthcare industry for the aged, and applying health information in the real-world studies. The rapid change and development of China’s medical and health reform policy have been attracted great attention by the international pharmaceutical companies.

Health technology assessment and pharmacoeconomic evaluation have developed rapidly in China in recent years. Under the leadership of Professors Liu Guo-En and Wu Jing, the 2011 edition of the Guidelines for the Evaluation of Chinese Pharmacoeconomics are being revised. Pharmacoeconomics special issues and sections have been established in newspapers and journals, such as Medicine Economic Report, Chinese Pharmacoeconomics journal, China Medical Insurance journal, Chinese Health Economics and Chinese Pharmacy journals. These provide a platform for the dissemination of the concepts and knowledge of pharmacoeconomics and outcomes research.

Health technology assessment and pharmacoeconomics have played an active role in drug pricing and reimbursement and drug policy research in China. The first batch of 121 rare diseases listing was published in China in 2018. It will promote the research and development of orphan drugs and market access. China participates in the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Management Committee to promote the reform of China’s drug approval system and accelerate the realization of drug accessibility. The National Essential Medicine List of the 2018 edition was released, the number of essential medicine increased to 685. Twelve anti-cancer drugs, 22 drugs that children urgently need in clinic, and a new pan-genotype hepatitis C DAA drug Epclusa (Sofosbavir + Velpatasvir) were also newly included. Vaccine management is being separately legislated. Special priority review of drugs has been further accelerating in importation of orphan drugs, such as Ikuzumab injection, Selexipag Tablets for pulmonary hypertension and Emicizumab injection for hemophilia. Drug clinical trials are licensed and imported anticancer drugs are subject to a new zero-tariff policy. Opdivo, the first anti-PD-1 drug, has been approved for sale in China. Fruquintinib, an innovative drug even not on the market at home and abroad, has been approved for listing.

In addition, China will continue to carry out consistency testing of drug quality and efficacy, and encourage research and development of innovative drugs, such as new anti-AIDS fusion inhibitor Albuvirtide for injection, the first domestic PD-1 antibody Tuoyi (拓益), anti-hepatitis C DAA drug Danoprevir (Ganovo), and anti-lung cancer drug Anlotinib hydrochloride capsules, have been approved for market.

Health Systems Updates

Real World Evidence in Asia Pacific

This section provides high level updates on the status of Real World Data in HTA from representatives of the ISPOR HTA Roundtable in Tokyo, Japan, as well as general health policy updates from participants of the ISPOR Asia Consortium Business Meeting in Barcelona. For more information on the ISPOR HTA Roundtable Asia Pacific, please visit here.

Australia – Continuing PBS Reforms

Adele Weston, PhD, Principal Scientist, Scientae Pty Ltd, Melbourne, Australia

Pricing reforms are still coming through from the 2015 PBS Reforms that will impact through 2020. These relate to the removal of originator brands from weighted price calculations that is estimated to result in about $2 billion in extra savings through 2020. In addition, the PBAC has determined that biosimilars are suitable for substitution at pharmacy level via an ‘a-flag’. There was a 2017-18 budget announcement about additional one-off price cuts for drugs that have been listed for more than 5, 10 and 15 years, as well as deeper price cuts when the first generic or biosimilar is listed. Another major reform is imminent – relating to the drug payment process for high cost PBS medicines. The changes attempt to address the budget implications associated with the delayed payment of large rebates from medicines companies back to Government, and inability of some community pharmacists to stock high cost medicines. A trial of the new payment arrangements will be implemented in consultation with the medicines supply chain for selected medicines from July 2019.  In essence the reform aims for medicines companies to only be remunerated throughout the year at the agreed effective price, rather than at the list price with sometimes-large rebates at the end of the year. However, wholesaler and pharmacy fees and mark-ups will continue to be calculated based on the list price of the medicine (in order to retain confidentiality of effective prices).

Bhutan – Overview of HTA practice

Deepika Adhikari, Senior Program Officer, Essential Medicines and Technology Division, Department of Medical Services, Ministry of Health, Thimphu, Bhutan

Bhutan heavily relies on WHO guidance for most of its health decisions. The Essential Medicines and Technology Division (EMTD, under MOH) was established in 2008. The introduction of any health interventions and technologies must be evidence-based and approved by the Health Intervention and Technology Assessment Panel (HTAP). This was written into the National Health Policy in 2011. As a result, the HTA Guideline was developed in 2013 by the EMTD, and a large amount of funds were designated to HTA activities from 2015 onwards. Several HTA activities resulted in implementation of health policies, such as introduction of mammography, acupuncture therapy, GeneXpert machine for detection of Rifampicin resistance, and others. The concepts of RWD and RWE are fairly new to Bhutan although it largely relies on RWD for decision making due to unavailability of randomized control trials (RCTs). Real world data mainly come from annual household surveys and medical records. These data are centralized by the Ministry of Health and published in the Annual Health Bulletin. Currently the Electronic Patient Information System is being developed, which would greatly benefit the generation and use of RWD in Bhutan.

India – Policy Perspectives on Real World Evidence

Devarshi Bhattacharyya, MSc, MPH, Assistant Director, Kalam Institute of Health Technology (KIHT), Visakhapatnam, India

The Indian healthcare market is a scattered market having a big potential. It is worth about $100 billion US dollars so far and estimated to reach $280 billion in 2020. 75% of the healthcare market is dominated by the private healthcare sector with the payments being mostly out of pocket expenditures. The Government has recently started Ayushman Bharat, a National Health Protection Scheme, which could be the world’s biggest insurance program in terms of the volume of patients covered. Real word evidence is still in its infancy in India. Currently there is no policy in a real-world perspective. While it is not used much currently in the national healthcare scenario, some clinicians and private care hospitals do use them; however claims data are not really used due to a low penetration of insurance providers. The clinical practice of doctors depends on disease-based outcomes rather than patient-reported outcomes for decision making. However, some projects of the Government do rely on RWE. For example, some state governments have set up “health ATMs” to do real-time monitoring of patients in some hospitals and primary health centers. An HTA body established under the Department of Health Research has identified RWE as an important part of HTA and policy for RWE in HTA is being formulated. A pilot study by the Andhra Pradesh government has been done for examining RWE in India.

Indonesia – Challenges in Conducting HTA and Implementing its Results

Sudigdo Sastroasmoro, MD, PhD, Chair of HTA Committee, Ministry of Health, Jakarta, Indonesia

Health Technology Assessment was introduced in Indonesia in 2001 at the Directorate General of Health Care, Ministry of Health, however for many years the assessments did not include formal economic evaluation. In 2014, the national HTA Committee was established right after the Government launched the national health insurance program aiming to implement universal health coverage. The HTA Committee currently was under the supervision of the Secretary General of the Ministry of Health. Since its establishment, the Committee has been collaborating with international agencies including WHO, HITAP, iDSI, PATH, AIPHSS, HTAsialink, and HTAi. With their support, many HTA studies have been completed. A HTA roadmap was developed aiming at establishing an independent HTA commission by 2026. In the future the assessments will be conducted by universities and research institutions, and the results will be appraised by the Committee. Currently there is only a limited amount of outcomes research in Indonesia, and almost 100% of clinical data come from international literature. Those factors pose significant challenges on Indonesia for conducting HTA and implementing HTA findings. Real world data are collected mostly from large hospitals in Java which are quite different from smaller hospitals especially outside Java. The quality of RWD is in general also unsatisfactory at the present time.

Hong Kong – Healthcare System Developments

Vivian WY Lee, PhD, Associate Professor, Chinese University of Hong Kong, Hong Kong, China

In 2019, a new children’s hospital will be opening as well as a new private hospital related to the Chinese University of Hong Kong. Meanwhile, the public hospitals will be expanding and implementing new programs. Lastly, Hong Kong is looking into a long term medical insurance plan. This year, the Government has explored tax exemptions for citizens who have already purchased long term medical insurance. This has created impact in the private and public health sector with examples of discussion for rare disease management and drug choices.

New Zealand – The Role of Real World Evidence

Richard Milne, PhD, Managing Director, Health Outcomes Associates Ltd, and Associate Professor, School of Population Health, University of Auckland, Auckland, New Zealand

New Zealand’s healthcare data are organized within the Integrated Data Infrastructure (IDI) and linked to multiple social sector datasets at individual level. This provides a unique platform for research. Issues of privacy, confidentiality and data security have been addressed through encryption and other security measures. While observational studies have been conducted by the IDI using local research, New Zealand’s national reimbursement agency PHARMAC makes its decisions based mainly on RCTs and local factors. It is thus recommended that RWE should be used more, as it provides complementary information, such as the appropriate country, the appropriate patient group(s) and local costs. Although local RWE is unavailable to inform the initial funding decisions, it provides a powerful tool for checking whether an intervention should continue to be funded, quantify its impact, and adjust prices.

Singapore – Continuing developments in HTA

Country updates provided by: Kwong Hoe Ng, Head, Evaluation and Appraisal, Agency for Care Effectiveness, Ministry of Health, Singapore; and Nan Luo, PhD, Associate Professor, National University of Singapore, Singapore

The Agency for Care Effectiveness (ACE, under MOH), a national HTA agency, was established in 2016. The ACE first focused in pharmaceuticals and started to expand the HTA capability on evaluating medical technology (medical devices, diagnostics, and medical services) in late 2016. So far the ACE has completed over 40 evaluations for pharmaceuticals and generated quite a few pieces of guidance, and it also published the Drug Evaluation Methods and Process Guide in early 2018, providing more transparency into how the appraisal process for economic evaluation is handled by the agency.

South Korea – Real World Evidence and HTA

Sukyeong Kim, PhD, Senior Research Fellow, Evidence-based Research Department National Evidence-based Health Care Collaborating Agency (NECA), Seoul, South Korea

National research and development programs funded by the Government have been developed in 2015 for supporting generation of RWE. The programs help build comprehensive patient registries including data of comparative effectiveness and cost effectiveness studies. Currently 27% of NECA research uses the national health insurance (NHI) data and the trend is increasing for more NHI data usage and linkage. The Government strongly supports health interventions in the research stage for the safety and effectiveness of evidence generation. In some cases of very high cost drugs for rare diseases, if regulators don’t have sufficient clinical evidence, financial-based risk sharing agreements can be applied. In Korea, there is a big interest in RWE in clinical and industry spaces. Challenges surrounding the quality of evidence, outcome types, and stakeholder participation are also being discussed and confronted.

Universal Health Care Coverage Reforms

Seungjin Bae, PhD, Associate Professor, Ewha Womans University, College of Pharmacy, Seoul, South Korea

“Mooncare,” named after South Korea President Moon Jae-In, has been proposed in 2018 with the aim to decrease patient expenditures with an accompanying increase in benefits coverage. With respect to drugs, expensive cancer drugs have been frequently cited because of their accessibility issues mainly due to their high price and uncertain economic value. This legislation has also been debated on the aspect of whether it should be more widely applied to increase accessibility and extend the current scope of universal coverage or remain a framework for control over future budget growth and sustainability.

Taiwan – Real World Data Experience in HTA

Churn-Shiouh Gau, PhD, Chief Executive Director, Center for Drug Evaluation (CDE), Taipei, Taiwan

Real world data are currently used in Taiwan’s HTA process in Taiwan, as well as budget impact analyses (BIA) as they are acknowledged to provide more relevant and reliable estimates than randomized clinical trials by many in the government and academia. Real world data are also used in local pharmacoeconomic evaluation studies which support the National Health Insurance’s (NHI) decisions for new technology coverage and listing prices, including reimbursement decisions on vaccines, medical devices and cochlear implants. Real world data sources in Taiwan are classified into two categories: 1) Patient-level Data of Nation-wide Population including NHI claims databases, cancer registry databases, and cause-of-death databases (these databases can be accessible by researchers after approval); and 2) Summary Data of National Health Statistics. The Government established the data linkage between healthcare databases from government agencies in 2011 and the Health Welfare Data Science Center. The Center manages all health and social welfare related databases including NHI claims database, registries, health survey, and disease-specific databases.

Managed-Entry Agreements for High Cost Drugs

Raoh-Fang Jasmine Pwu, PhD, Director, National Hepatitis C Program Office, Ministry of Health and Welfare, Taipei, Taiwan

For high-cost oncology drugs, which cost more than 500 Million Taiwan Dollars nationally per year, the NHIA has announced Managed Entry Agreement (MEA) rules. There are 6 types of arrangements that the applying company can choose for their therapy. Additionally, patient groups have raised the question on the impact of the patient involvement process for health care decision making in Taiwan, and they are looking to strengthen the process. Some of the groups plan to build their own patient evidence reserves in order to have a dialogue with the decision makers.


ISPOR Asia Consortium HEOR Survey – Please Provide Your Feedback

 ISPOR Asia Consortium is undertaking a region-wide HEOR topics survey to inform our members and staff on the high priority scientific and policy trends for 2019 and beyond. This survey will be a major source of information for our consortium content strategy, as well as 2020 conference. Please take a moment and provide us with your invaluable feedback! Survey link:

ISPOR’s mission to improve health care decision making globally, so it is of great interest to us that our knowledge products are being utilized at the local and national decision-making levels. If you have any knowledge of the use of the ISPOR Good Practice Reports by governmental/regulatory bodies in your respective country, please let us know at

APO Issued a Call for Reviewers and new Health Systems Publications

The Asia Pacific Observatory on Health Systems and Policies (APO) of WHO SEARO has issued a “Call for Expression of Interest in Serving as an Internal Review Panel Member” for experienced health systems researchers. For more information, visit:

New Health Systems Reports Published by APO

The APO has also published 2 new health systems reports entitled “Philippines Health System Review” and “Resilient and People-Centered Health Systems: Progress, Challenges and future directions in Asia.”

Survey on Preventing and Controlling NCDs: Welcome your Participation

A global consortium of experts are creating an evidence package on non-communicable disease (NCD) prevention in low- and middle-income countries called “Best Buys, Wasted Buys and Controversies in NCD prevention”. 

To inform the project, leading researchers at Harvard University have designed a survey to learn more about the experiences and challenges in preventing and controlling NCDs. You are invited to participate in the survey linked here. The survey should not take longer than 20 minutes to complete and will close on 30th January 2019. This work is led by HITAP and supported by the Prince Mahidol Award Conference (PMAC), the International Decision Support Initiative (iDSI) and the Thai Health Promotion Foundation. *ISPOR did not contribute to the development of this survey.

Academic Job Vacancy in Pakistan

There is a new job posting available for the position of Associate Professor of Health Economics and Finance at Aga Khan University, Karachi, Pakistan. For more information, please visit the ISPOR Pakistan Chapter website.

Textbook Published on Clinical Pharmacy Education, Practice and Research

Edited by Dr. Dixon Thomas, a member of ISPOR Asia Consortium, this book covers educational approaches that empower pharmacists with patient care and research competencies, serving as a basis to standardize and coordinate learning to practice, explaining basics and using self-learning strategies through online resources or other advanced texts. For more information, visit here.

Auburn University Health Outcomes Research and Policy PhD Program

The Harrison School of Pharmacy at Auburn University is actively recruiting students for admission to the PhD program in Health Outcomes Research and Policy for the fall of 2019. The program emphasizes the rigorous application of quantitative methods in health services research and pharmacoepidemiology, as well as intervention implementation and analysis, survey research, and qualitative methods. Teaching and/or research assistantships are awarded to qualified graduate students on a competitive basis. To learn more, please visit

HEOR Certification Program in India

MarksMan HealthCare Communications, a scientific outsourcing and research consulting company based in India, has introduced an introductory HEOR certification program. For more information please visit here. *Please note that this program is not affiliated with the ISPOR Educational program.

New 2018-2019 Executive Committee Team for ISPOR Singapore Chapter

On September 21, 2018, ISPOR Singapore Chapter held their annual general meeting and elected the new executive committee team. The new members of the Executive Committee are:

  • Assistant Professor Wee Hwee-Lin as President
  • John Tayu Lee as Immediate Past President
  • (Viva) Yan Ma as Vice President
  • Caitlin Asjes as Treasurer
  • Brandon Chua as Secretary

Upcoming Workshop on “Advanced Modelling Techniques in HTA and RWE Generation” in Singapore

ISPOR Singapore Chapter will host a workshop on “Advanced Modelling Techniques in HTA and RWE Generation on 26-27 February 2019. Modelling expert Dr. Jaime Caro will present on several simulation techniques including Discretely Integrated Condition Event (DICE), simulations to address missing head to head clinical trials, and simulation techniques to improve efficiency of post marketing registries (SAVES).

ISPOR 2019 Outstanding Regional Chapter Award

ISPOR Chapter Presidents are encouraged to fully and diligently submit their annual reports on time by January 31, 2019 to qualify the Chapter for the 2019 Outstanding Regional Chapter Award. The Award program recognizes outstanding contribution and leadership of ISPOR Regional Chapters in advancing ISPOR’s mission in ISPOR global regions – Asia, Latin America, and Europe, Middle East, and Africa. ISPOR staff assess the Chapters contributions by applying eligibility and selection criteria in their review of the information available from the Chapter Annual Reports, chapter input to the ISPOR publications and ISPOR activities throughout the year. The award consists of a trophy, an amount of 1000 USD per winning Chapter (available as a credit against the future Chapter educational events), interview in VOS and a complimentary Annual European Congress registration for the Chapter delegate who will be receiving an award. For more information about the award criteria and selection process, please visit ISPOR Outstanding Regional Chapter Award Program.

ISPOR Travel Grant Supports HEOR Professionals from Low- and Middle-Income Countries

The ISPOR Travel Grant is one of the many benefits offered to ISPOR members from Low- and Middle-Income countries to support their participation and engagement during the ISPOR annual conference in North America and Europe and biannual regional conferences in Latin America and Asia Pacific. Members are encouraged to visit the ISPOR Travel Grant webpage for more information including applications, eligibility criteria, and the nature of the ISPOR Travel Grant. We are currently accepting applications for ISPOR 2019 in New Orleans, USA. The application deadline is Monday, February 18, 2019.

During the application submission period for ISPOR conferences in 2018, there were over two hundred applications that were carefully reviewed by the ISPOR Conference Travel Grant Committee to choose 39 of the most qualified recipients of the ISPOR Travel Grant. 17 recipients from the EMEA region, 20 from the Asia Pacific region, and 2 from Latin America were given the opportunity to attend ISPOR conferences during 2018. ISPOR Conferences allow members to discover the latest developments in health economics and outcomes research (HEOR). “The new methods which I obtained during this meeting will be very useful to design new practical approaches for implementation in our domestic health care system,” says Viktoriia Dobrova, ISPOR 2018 Travel Grant winner from Ukraine.

The knowledge acquired at ISPOR conferences is intended to be brought back to the ISPOR Travel Grant recipients’ regions to continue the development and impact of HEOR worldwide. Complimentary registrations to ISPOR Short Courses are part of the award to develop such learning. Mamatha Murthy from India, ISPOR Asia Pacific 2018 Travel Grant winner reflects, “ISPOR short courses offered a variety of basics to newer developments which has influenced me to adopt such work flow to improve the patient care in terms of economic and health benefit at my health care setting. I have been entrusted on learning and transferring this systematic knowledge on pharmacoeconomics to my students and colleagues and other health care professionals in my setup to initiate and extend it to patient care services.”

With thousands of attendees at each ISPOR conference, ISPOR Travel Grant recipients are offered a platform to network with peers and colleagues who are involved in HEOR globally. These new connections often lead to collaboration on future projects and initiatives. Saul Espinoza from Peru, ISPOR Europe 2018 Travel Grant winner says, “I was able to enrich my knowledge in Health Economics and Outcomes Research. I was able to present a study made in my region through a poster and I was able to keep relationships with people from different parts of the world. You have given me a great motivation to continue with this interesting branch of healthcare.”

Recent Events

ISPOR Participation at the National HTA Conference in China

The 1st China HTA Conference was convened on October 26, 2018 in Beijing, China on “Value-based Health Care, Priority Setting in Health.” The Conference marked the critical milestone of opening of the China National HTA Center based at the National Health Development Research Center, of the National Health Commission, Beijing, China. Dr. Kun Zhao, The Conference drew nearly 1,000 delegates from various fields such as government, academia, clinicians, pharmaceutical and medical device industry, and health technology companies. Top government officials in attendance included the Vice Minister of the National Health Commission (MOH) and Deputy Director of National Insurance Bureau spoke at the conference. ISPOR featured a presentation during the 1st Plenary Session which was presented by Dr. Finn Boerlum Kristen, Chair of ISPOR HTA’s Council. There were also roundtable discussions on HTA of Innovative Cancer Drugs which included multiple stakeholder perspectives including patients. There will a second National HTA Conference in China in October 2019, and ISPOR will be participating as well as holding concurrent HTA training, HTA and Patient roundtables and other meetings.

1st China HTA Conference in Beijing


4th Global Forum on Medical Devices in Vishakhapatnam, India

ISPOR participated in the 4th WHO Global Forum on Medical Devices on 13-15, December 2018 in Visakhapatnam, Andhra Pradesh, India. The theme of the Forum was “Increasing Access to Medical Devices,” and had 600 participants from over 100 Member States. These events function as the main opportunity to disseminate and share information on medical devices for global health. ISPOR is currently undertaking several new initiatives regarding medical devices including collaborating with the WHO.

Modeling Workshop in the Philippines

ISPOR Philippines Chapter recently held a session on Bayesian & Markov Modelling: A Case Study on Vaccination on October 3, 2018. The workshop focused on the application of computational statistics in actual health care problems to quantify the cost of living for use in decision making. Two methods were presented, including Bayesian statistics and Monte Carlo simulation. A case study around vaccination was used to demonstrate the above two methods, and there was discussion centered around data quality and assumptions which affect results’ accuracy. For more information, please visit the ISPOR Philippines Chapter website.

Training on Pharmacoeconomics held in Mongolia

ISPOR Mongolia Chapter organized a one-day training entitled “A training on Pharmacoeconomic studies and Health System Outcomes Research” on September 18, 2018 for academic faculty members, professionals in the health sector of Mongolia” for health professionals, decision-makers and academic faculty in the health sector of Mongolia. More than 20 members participated and representatives from both public and private organizations, such as the Ministry of Health, Health Insurance Office, Public Health Institution, academic institutions, pharmaceutical industries and Achtan Eji hospital were represented, among others. For more information, please visit ISPOR Mongolia Chapter website.


Join ISPOR – to access our world class journals Value in Health, Value in Health Regional Issues and Value in Outcomes Spotlight, join global groups, participate in our special interest groups and task forces, get involved in leadership initiatives and stayed informed on HEOR news and trends, join or renew your membership to the Society today!

ISPOR Chapter Annual Reports

For ISPOR Regional Chapter Presidents: ISPOR Chapter Annual Reports are due in English on January 31, 2019. Chapters that want to be considered for the Outstanding Chapter Award should submit fully complete annual reports by the deadline for qualification. Chapters that don’t submit their reports may risk losing their status.

ISPOR Travel Grant Deadlines

ISPOR 2019: New Orleans, May 18-22, 2019

  • Monday, February 18: Application Deadline
  • Monday, March 18: Notification Deadline

ISPOR Europe 2019: Copenhagen, 2-6 November 2019

  • Monday, 5 August: Application Deadline
  • Thursday, 5 September: Notification Deadline

Call for Abstracts Deadlines

  • ISPOR 2019 – January 16, 2019
  • ISPOR Latin America – 13 March 2019
  • ISPOR Europe – 12 June 2019

Chapter Leadership Training Workshop

Thank you to those Chapter leaders that participated in the ISPOR Chapter Leader Training Program in ISPOR 2018, Baltimore and Barcelona. There will be trainings scheduled for May and November 2019 in conjunction with the ISPOR International and European Conferences, as well as an educational webinar surrounding topics on leadership skills training and chapter management. For more information and to participate, please contact

Update your ISPOR member profile

Your ISPOR member profile is important for you to join and maintain your ISPOR group relationships (such as Consortia, SIGs and Committees), access your and manage your event registrations, certificates and journals, submit your manuscripts for ViH and ViHRI, and manage your communications access, providing permissions to receive notifications from ISPOR.

Please activate your user profile in the new system to access ISPOR’s HEOR content and resources with a single sign-on, including Value in Health and Value in Health Regional Issues articles, Good Practices for Outcomes Research Reports, and other HEOR resources. To activate your user profile, please:

  1. Visit the new, redesigned ISPOR website at
  2. Click the green “Log in” button in the top right corner.
  3. Enter your email address and password
  4. You will be requested to change your password
  5. Please use ‘Forgot Your Password’ to reset your password if needed.

Asia Consortium Schedule of Events for 2019

  • Educational Webinar – March
  • News Across Asia Spring Issue – April
  • Asia Consortium Meetings during ISPOR 2019 – May
  • Chapter leadership training during ISPOR 2019 – May
  • News Across Asia Summer Issue – July
  • ISPOR HTA Training Program, HTA and Patient Roundtable – October
  • News Across Asia Autumn Issue – October
  • Educational Webinar – November
  • Chapter leadership training during ISPOR Europe 2019 – November
  • Asia Consortium Meetings during ISPOR Europe 2019 – November

Join ISPOR Asia Consortium or renew your membership.

© 2019 International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
505 Lawrence Square Blvd. South, Lawrenceville, NJ 08648 USA